首页|瑞舒伐他汀联合法舒地尔对慢性阻塞性肺疾病合并肺动脉高压患者的疗效及安全性评价

瑞舒伐他汀联合法舒地尔对慢性阻塞性肺疾病合并肺动脉高压患者的疗效及安全性评价

扫码查看
目的 探究瑞舒伐他汀联合法舒地尔对慢性阻塞性肺疾病(COPD)合并肺动脉高压患者的疗效及安全性。方法 采用随机数表法将 2020 年 2 月至 2022 年 3 月滨州市中心医院收治的COPD合并肺动脉高压患者 80 例分为两组,每组各 40 例,对照组采用瑞舒伐他汀治疗,观察组在其基础上增加法舒地尔治疗,比较两组临床疗效,治疗前后肺功能及肺循环指标、心室重构指标,同时观察不良反应。结果 观察组临床总有效率明显高于对照组,差异有统计学意义(P<0。05)。治疗后观察组第 1 秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、三尖瓣最大反流速度(TRVmax)、右室射血分数(RVEF)、右心室梗死(RVMI)高于对照组,静息状态平均动脉压(MPAP)、主动脉内径(AO)、右心室舒张末期基底横径(RVDD)低于对照组,差异有统计学意义(P<0。05)。两组治疗期间不良反应比较,差异无统计学意义(P>0。05)。结论 瑞舒伐他汀联合法舒地尔对COPD合并肺动脉高压患者的临床效果突出,可有效改善患者的肺功能及肺循环指标,同时心室重构指标也得以改善,治疗期间无明显不良反应,安全性较高。
Evaluation of the efficacy and safety of rosuvastatin combined with fasudil in patients with chronic obstructive pulmonary disease complicated with pulmonary hypertension
Objective To explore the efficacy and safety of rosuvastatin combined with fasudil in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary hypertension.Methods A total of 80 patients with COPD complicated with pulmonary hypertension admitted to Binzhou Central Hospital from February 2020 to March 2022 were divided into two groups according to the random number table method,with 40 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with fasudil on the basis of rosuvastatin.The clinical efficacy were compared,including lung function,pulmonary circulation indicators,and ventricular remodeling indicators before and after treatment,and adverse reactions were observed between the two groups.Results The total clinical effective rate of the observation group was significantly higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the observation group had higher first second forced expiratory volume(FEV1),FEV1/forced vital capacity(FVC),tricuspid valve maximum reflux velocity(TRVmax),right ventricular ejection fraction(RVEF),right ventricular infarction(RVMI),and mean pulmonary arterial pressure(MPAP),aortic diameter(AO),and right ventricular end-diastolic basal transverse diameter(RVDD)compared to the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in adverse reactions between the two groups during treatment(P>0.05).Conclusion The combination of rosuvastatin and fasudil has a prominent clinical effect on COPD patients complicated with pulmonary hypertension,effectively improving lung function and pulmonary circulation indicators,as well as improving ventricular remodeling indicators.There are no significant adverse reactions during the treatment period,with high safety.

RosuvastatinFasudilChronic obstructive pulmonary diseasePulmonary hypertensionEfficacySafety

李新、尹彦海、马志英、王孟、张学平

展开 >

山东省滨州市中心医院呼吸内科,山东滨州 251700

山东省滨州市中心医院肿瘤科,山东滨州 251700

瑞舒伐他汀 法舒地尔 慢性阻塞性肺疾病 肺动脉高压 疗效 安全性

滨州医学院科研启动基金项目

BY2019KJ77

2024

中国医药科学
海峡两岸医药卫生交流协会 二十一世纪联合创新(北京)医药科学研究院

中国医药科学

影响因子:1.083
ISSN:2095-0616
年,卷(期):2024.14(1)
  • 15